You are on page 1of 2

The following Overview, *** BUTYLATED HYDROXYTOLUENE ***, is relevant for this HSDB record chemical.

Life Support:
o This overview assumes that basic life support measures have been instituted.

Clinical Effects:
0.2.1 SUMMARY OF EXPOSURE 0.2.1.1 ACUTE EXPOSURE A) The clinical manifestations of acute overdose are not well known. Ingestion of 4 grams produced gastritis, dizziness, confusion, and temporary loss of consciousness in an adult. BHT dust is irritating if in contact with the eyes, nose or throat. Chronic toxicity in animals is related to potassium depletion. 0.2.4 HEENT 0.2.4.1 ACUTE EXPOSURE A) BHT dust is irritating to the eyes, nose, and throat. 0.2.7 NEUROLOGIC 0.2.7.1 ACUTE EXPOSURE A) Weakness, dizziness, and brief loss of consciousness have been reported in an adult who ingested 4 grams. B) Hallucinations, ataxia, and dysarthria were seen in an adult who ingested 80 grams. 0.2.8 GASTROINTESTINAL 0.2.8.1 ACUTE EXPOSURE A) Epigastric pain and vomiting have been reported in overdose. 0.2.12 FLUID-ELECTROLYTE 0.2.12.1 ACUTE EXPOSURE A) Hypokalemia may be noted. 0.2.15 MUSCULOSKELETAL 0.2.15.1 ACUTE EXPOSURE A) Muscle weakness may be noted in conjunction with potassium depletion. 0.2.20 REPRODUCTIVE HAZARDS A) Conflicting data appear regarding teratogenicity. BHT is excreted in the breast milk of rats. 0.2.21 CARCINOGENICITY 0.2.21.1 IARC CATEGORY A) IARC Carcinogenicity Ratings for CAS128-37-0 (IARC, 2004): 1) IARC Classification a) Listed as: Butylated hydroxytoluene (BHT) b) Carcinogen Rating: 3 1) The agent (mixture or exposure circumstance) is not classifiable as to its carcinogenicity to humans. This category is used most commonly for agents, mixtures and exposure circumstances for which the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals. Exceptionally, agents (mixtures) for which the evidence of carcinogenicity is inadequate in humans but sufficient in experimental animals may be placed in this category when there is strong evidence that the mechanism of carcinogenicity in experimental

CO. Usual dose: 25 to 100 g in adults/adolescents. Treatment Overview: 0. 2005. Inc. D) Fluid and electrolyte abnormalities should be corrected if noted. C) EMESIS: Ipecac-induced emesis is not recommended because of the potential for CNS depression.4. edition expires Feb.2 ORAL EXPOSURE A) DILUTION: Immediately dilute with 4 to 8 ounces (120 to 240 mL) of water or milk (not to exceed 4 ounces/120 mL in a child). p. 2005. Hall AH & Rumack BH (Eds): TOMES(R) Information System Micromedex. CCIS Volume 123. 25 to 50 g in children (1 to 12 years). mixtures and exposure circumstances that do not fall into any other group are also placed in this category.. 2005. Laboratory: A) Fluid and electrolyte status should be monitored. Englewood. [Rumack BH POISINDEX(R) Information System Micromedex.. Inc. edition expires Feb. CCIS Volume 123. Range of Toxicity: A) The average dietary intake in the United States is 2 mg. B) Moderate symptoms were produced in an adult who ingested 4 grams. CO.. ]**PEER REVIEWED** . with particular attention to serum potassium levels.animals does not operate in humans. and 1 g/kg in infants less than 1 year old. Englewood. 2005. Agents. B) ACTIVATED CHARCOAL: Administer charcoal as a slurry (240 mL water/30 g charcoal).